The quantifiable range of these 13 targets and CD9 ranged from 0.003 ng/mL (for ART4) to 5.50 ng/mL (for CD9) in HCs and from 0.13 ng/mL (for ART4) to 7.66 ng/mL (for CD9) in CRC patients. Here, ART4 is linked to colorectal carcinoma.